News

The company plans to start a commercial launch of the drug in major European countries in early next year. Earlier this year, the European Medicines Agency’s Committee for

TBRIA is a once-daily oral recombinant salmon calcitonin tablet for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause when alternative treatments are not suitable

While current HIV treatments involve pills that are taken daily, the new regimens’ long-lasting effects suggest that HIV treatment could be administered perhaps once or twice per year.

Shire has recently completed a Phase 3 study of lifitegrast, OPUS-3, that is expected to be the basis of Shire’s response to the CRL. The FDA also requested

The funding will be used for the study to discover antibodies against Ebola virus and identify how they prevent Ebola virus infection, allowing to develop Ebola therapeutics and

The company said that the results of the trial were not statistically significant, in which the primary endpoint of change from baseline in the six-minute walk test (6MWT)

The deal is expected to generate more than $200m for Emisphere. Under the deal, Emisphere will receive a $5m upfront licensing fee from Novo Nordisk, and is eligible

The program also includes FPA008 which is in its initial development stage for immunology as well as oncology indications. Under the terms of the agreement, Five Prime will

Resunab is a novel oral drug designed to target the resolution of chronic inflammation and debilitating fibrosis associated with disease progression in CF across all cystic fibrosis transmembrane